MENU
+Compare
ERAS
Stock ticker: NASDAQ
AS OF
Oct 27, 04:59 PM (EDT)
Price
$2.39
Change
+$0.01 (+0.42%)
Capitalization
675.13M

ERAS Erasca Forecast, Technical & Fundamental Analysis

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers... Show more

ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ERAS with price predictions
Oct 24, 2025

ERAS's RSI Oscillator recovers from overbought zone

The 10-day RSI Oscillator for ERAS moved out of overbought territory on October 17, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 21, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ERAS as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ERAS turned negative on October 17, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 50-day moving average for ERAS moved above the 200-day moving average on September 30, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in of 210 cases, the price rose further within the following month. The odds of a continued upward trend are .

ERAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 84 cases where ERAS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.814) is normal, around the industry mean (24.410). P/E Ratio (0.000) is within average values for comparable stocks, (54.672). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.161). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (355.200).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ERAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ERAS is expected to report earnings to fall 13.33% to -10 cents per share on November 05

Erasca ERAS Stock Earnings Reports
Q3'25
Est.
$-0.10
Q2'25
Est.
$-0.12
Q1'25
Beat
by $0.02
Q4'24
Beat
by $0.02
Q3'24
Beat
by $0.06
The last earnings report on August 12 showed earnings per share of -11 cents, meeting the estimate of -11 cents. With 356.66K shares outstanding, the current market capitalization sits at 675.13M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
3115 Merryfield Row
Phone
+1 858 465-6511
Employees
126
Web
https://www.erasca.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HOOYX32.140.29
+0.91%
Hartford Schroders US Small Cap Opps Y
FSZZX11.830.10
+0.85%
Fidelity Advisor Sustainable EM Eq Z
IOAPX31.830.22
+0.70%
Invesco Main Street All Cap R6
OASVX13.250.06
+0.45%
Optimum Small-Mid Cap Value A
PRRAX28.870.11
+0.38%
Principal Real Estate Securities A

ERAS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+7.69%
XNCR - ERAS
55%
Loosely correlated
+7.05%
OCUL - ERAS
52%
Loosely correlated
+0.44%
RVMD - ERAS
48%
Loosely correlated
+1.95%
CRNX - ERAS
48%
Loosely correlated
+2.27%
IDYA - ERAS
48%
Loosely correlated
+2.67%
More